Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (10646)	2/26/2004 1:48:51 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

<CRIS> Can't say I've followed them for quite a while - but my interest is kept alive by their IP in hedgehog pathways. May never turn into dollars, but clearly worth keeping an eye on. For example, here's an interesting article on diabetic neuropathy: J. Clin. Invest. 111:507-514 (2003) Copyright ©2003 by the American Society for Clinical Investigation Article Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy ncbi.nlm.nih.gov:80/entrez/utils/fref.fcgi?http://www.jci.org/cgi/pmidlookup?view=full&pmid=12588889 And there were also some neat-sounding PR's relating to spinal cord injury if my memory serves me correctly. It's of course hard to know what to do in valuation terms with companies that might have good IP but don't have a product. Mostly they seem to end up fizzling. (I'm thinking companies like the old SNAP). Peter